{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2016-05-06&_metadata=all&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "items" : [{"_about" : "http://data.parliament.uk/resources/514044", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/514044/answer", "answerText" : {"_value" : "<p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department\u2019s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department\u2019s policies.<\/p><p>The answer of 23 March 2016 stated, \u2018data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.\u2019 This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.<\/p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "34694"}
        , {"_value" : "34695"}
        , {"_value" : "34696"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-25T14:55:51.253Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department's policies of the findings from the 2014 paper by Kavanagh and others, Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "34693"}
    , {"_about" : "http://data.parliament.uk/resources/514045", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/514045/answer", "answerText" : {"_value" : "<p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department\u2019s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department\u2019s policies.<\/p><p>The answer of 23 March 2016 stated, \u2018data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.\u2019 This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.<\/p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "34693"}
        , {"_value" : "34695"}
        , {"_value" : "34696"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-25T14:55:51.33Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether the time period referred to when providing details of the not anticipated reduction in genital warts associated with the bivalent vaccine takes into account the impact of the introduction of the quadrivalent vaccine in 2012.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "34694"}
    , {"_about" : "http://data.parliament.uk/resources/514075", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/514075/answer", "answerText" : {"_value" : "<p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department\u2019s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department\u2019s policies.<\/p><p>The answer of 23 March 2016 stated, \u2018data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.\u2019 This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.<\/p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "34693"}
        , {"_value" : "34694"}
        , {"_value" : "34696"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-25T14:55:51.407Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether there has been any lasting duration of the HPV reduction that Public Health England have associated with the bivalent vaccine.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "34695"}
    , {"_about" : "http://data.parliament.uk/resources/514076", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/514076/answer", "answerText" : {"_value" : "<p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department\u2019s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department\u2019s policies.<\/p><p>The answer of 23 March 2016 stated, \u2018data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.\u2019 This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.<\/p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "34693"}
        , {"_value" : "34694"}
        , {"_value" : "34695"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-25T14:55:51.47Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department's policies of the 2016 paper by Mesher and others, Reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "34696"}
    , {"_about" : "http://data.parliament.uk/resources/506518", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/506518/answer", "answerText" : {"_value" : "<p>As a provider of front line services, costs incurred by acute hospitals do not contribute to the Administration budget allocated to the Department. Therefore, for the Royal Devon and Exeter Hospital, and all other acute hospitals in England, none of the total expenditure incurred in 2014-15 was considered to be administrative cost.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
        }
        , "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
        , "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
        , "dateOfAnswer" : {"_value" : "2016-04-13", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-13T10:29:58.06Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hospitals: Administration"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the administrative costs as a proportion of spending were of (a) the Royal Devon and Exeter Hospital and (b) every other acute hospital in England in 2014-15.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "33112"}
    , {"_about" : "http://data.parliament.uk/resources/480636", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/480636/answer", "answerText" : {"_value" : "<p>The UK Cetacean Strandings Investigation Programme is currently working with experts from Germany and The Netherlands to carry out an assessment of all the potential factors, natural and/or human-induced, that may have contributed to the recent sperm whale strandings.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3934", "label" : {"_value" : "Biography information for George Eustice"}
        }
        , "answeringMemberConstituency" : {"_value" : "Camborne and Redruth"}
        , "answeringMemberPrinted" : {"_value" : "George Eustice"}
        , "dateOfAnswer" : {"_value" : "2016-03-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-24T16:49:02.167Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "13"}
      , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"}
      , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"}
      , "date" : {"_value" : "2016-03-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Whales: East of England"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the Answer of 22 February 2016 to Question 26471, whether the UK cetacean Strandings Investigation Programme plans to assess the potential link between oil and gas activities and related seismic testing and the movement of sperm whales to North Sea waters.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31729"}
    , {"_about" : "http://data.parliament.uk/resources/479633", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/479633/answer", "answerText" : {"_value" : "<p>The human papilloma virus (HPV) vaccination programme was introduced in 2008, when the bivalent vaccine Cervarix was administered. From September 2012, following a competitive tender exercise, the quadrivalent vaccine Gardasil was introduced.<\/p><p> <\/p><p>Both protect against the two strains of HPV (HPV16 and HPV18) that cause 70% of cervical cancer. Gardasil also protects against the two HPV types that cause around 90% of all genital warts (HPV6 and HPV11).<\/p><p> <\/p><p>A decrease in genital warts was not anticipated for the bivalent HPV vaccine, Cervarix. An estimate of the change in prevalence of genital warts has not been carried out.<\/p><p> <\/p><p>However, rates of genital warts in genito-urinary medicine (GUM) clinics have declined significantly amongst the population vaccinated. Data reported to Public Health England from GUM clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014 of 30.6% in 15-19 year-old females and 25.4% amongst same age heterosexual males.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-03-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-24T14:40:25.57Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-03-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the potential change in the prevalence of genital warts following the award of the contract for supply of human papillomavirus vaccine to the bivalent vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31529"}
    , {"_about" : "http://data.parliament.uk/resources/479194", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/479194/answer", "answerText" : {"_value" : "<p>The contract information for the supply for human papilloma virus vaccine to be used in the adolescent girls programme is expected to be placed into the public domain in Contracts Finder before the end of April 2016; the Contracts Finder can be found at the following link:<\/p><p> <\/p><p><a href=\"https://www.gov.uk/contracts-finder\" target=\"_blank\">https://www.gov.uk/contracts-finder<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-03-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-24T14:25:04.24Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-03-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when he expects a decision to be announced on the contract for the supply of human papilloma virus vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31334"}
    , {"_about" : "http://data.parliament.uk/resources/479201", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/479201/answer", "answerText" : {"_value" : "<p>Stakeholder representation on the Advisory Committee on the Safety of Blood Tissue and Organs\u2019 Donor Selection Criteria Working Group consists of the Terence Higgins Trust, National Aids Trust, Patients Association, Sickle Cell Society, Thalassemia Society and the LGBT Consortium. A Stakeholder meeting is planned alongside the first meeting of the Working Group and a wider range of stakeholders is to be invited. Relevant stakeholder representatives such as former sex workers and ex-intravenous drug users will be invited to attend the Working Group when it is considering particular aspects of donor selection criteria.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-03-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-24T14:29:09.833Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-03-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood: Donors"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 26 February 2016 to Question 28059, whether representatives of ex-intraveneous drug users and former sex-workers will be invited to sit on the working group being formed by the Advisory Committee on the Safety of Blood, Tissues and Organs as part of its review of blood donor selection criteria.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31304"}
    , {"_about" : "http://data.parliament.uk/resources/475638", "AnsweringBody" : [{"_value" : "Department for Communities and Local Government"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/475638/answer", "answerText" : {"_value" : "<p>The total number of homes completed under the Get Britain Building programme from its launch in November 2011 to September 2015 is 9,761. Of these, 1400 are affordable homes.<\/p><p>Government does not collect data concerning the number of jobs created by the Get Britain Building programme.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4009", "label" : {"_value" : "Biography information for Sir Brandon Lewis"}
        }
        , "answeringMemberConstituency" : {"_value" : "Great Yarmouth"}
        , "answeringMemberPrinted" : {"_value" : "Brandon Lewis"}
        , "dateOfAnswer" : {"_value" : "2016-05-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-05-09T15:41:37.743Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "7"}
      , "answeringDeptShortName" : {"_value" : "Communities and Local Government"}
      , "answeringDeptSortName" : {"_value" : "Communities and Local Government"}
      , "date" : {"_value" : "2016-03-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Housing: Construction"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Communities and Local Government, how many (a) homes and (b) affordable homes have been completed under the Get Britain Building scheme to date; and what estimate he has made of the number of new jobs created by that scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31113"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-date=2016-05-06&creator.label=Biography+information+for+Mr+Ben+Bradshaw", "page" : 0, "startIndex" : 1, "totalResults" : 238, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}